The prostate pathology core provides essential services to all projects in the SPORE with major commitment to tissue acquisition and processing, tissue histology and analysis including specialized techniques, and pathology consultation. The core is fully committed to collaboration with other SPORE and NCI programs, including the National Biospecimen Network (NBN), the Inter-SPORE Prostate Biomarker Study (IPBS), the NCI informatics grid (e.g. CA-BIG etc.), the Inter-SPORE Clinical Trial Concept Committee, and the Early Detection Research Network (EDRN). The core infrastructure includes a Pathology Coordinating Center which interacts with the SPORE Executive Committee to prioritize resources among competing projects. For tissue collection the core will expand existing resources including a functioning tissue bank funded by the Jonsson Cancer Center and the Departments of Pathology and Urology to provide services to the projects including harvesting, collection, and processing of fresh biopsy, prostatectomy, serum and urine specimens. Tissue will be collected from prostate core biopsies, prostatectomy specimens, trans-urethral resections, and metastatic tumor from surgical and autopsy specimens. All specimens will be evaluated pathologically by the Pi's (Dr. Said or Dr. Thomas) to ensure accurate and consistent classification and grading of tumors. The core will also provide a full range of services including processing, fixation, and embedding of human and murine tissues, routine histology, and specialized immunohistochemistry and in-situ hybridization studies. Particularly use will be made of high throughput techniques incorporating tissue arrays from over 500 cases of prostate carcinoma already prepared, as well as second generation arrays with samples related to outcome such as PSA recurrence and metastasis. A computerized database will be maintained of well-characterized matched samples of normal and neoplastic tissues. This database is electronically linked to the clinical database maintained by the SPORE Biostatistics core and the Department of Urology. The core will validate IRB approvals before performing studies, and will maintain patient confidentiality at all times. Core facilities include a histology laboratory, a fully automated immunohistochemistry laboratory, computerized instrumentation for quantitative immunohistochemistry, and a tissue array facility. One of the key contributions of this core is expert pathology consultative services. The Pi's have demonstrated expertise with prostate pathology, both clinical and experimental, involving human and murine tissue. The investigators will continue to work closely with SPORE investigators in experimental design, use of human and murine tissues, and analysis and interpretation of results. Drs. Said and Thomas have co-authored over 30 prostate cancer publications during the five years of SPORE funding, reflecting their engagement in the program and contribution of this core to prostate cancer research at UCLA.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092131-07
Application #
7679550
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
7
Fiscal Year
2008
Total Cost
$141,396
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Cheng, Larry C; Li, Zhen; Graeber, Thomas G et al. (2018) Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer. J Vis Exp :
Park, Jung Wook; Lee, John K; Sheu, Katherine M et al. (2018) Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 362:91-95
Tan, Nelly; Shen, Luyao; Khoshnoodi, Pooria et al. (2018) Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology. J Urol 199:1218-1223
Donin, Nicholas M; Reiter, Robert E (2018) Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J Nucl Med 59:177-182
Nagarajan, Mahesh B; Raman, Steven S; Lo, Pechin et al. (2018) Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. Abdom Radiol (NY) 43:2487-2496
Calais, Jeremie; Fendler, Wolfgang P; Eiber, Matthias et al. (2018) Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med 59:434-441
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control 29:581-588
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 122:76-82
Jelinek, David; Flores, Aimee; Uebelhoer, Melanie et al. (2018) Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue. J Vis Exp :
Lee, John K; Bangayan, Nathanael J; Chai, Timothy et al. (2018) Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A 115:E4473-E4482

Showing the most recent 10 out of 339 publications